TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
Chapter 5. Market Factor Analysis
5.1 Porters Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
Chapter 6. Global Bipolar Disorders Treatment Market, by Drug Type
6.1 Introduction
6.2 Mood Stabilizer
6.3 Anticonvulsant
6.4 Antipsychotic Drug
6.5 Antidepressant Drug
6.6 Other
Chapter 7. Global Bipolar Disorders Treatment Market, by Mechanism of Action
7.1 Introduction
7.2 Selective Serotonin Reuptake Inhibitor
7.3 Serotonin Norepinephrine Reuptake Inhibitor
7.4 Monoamine Oxidase Inhibitors
7.5 Beta Blockers
7.6 Tricyclic Antidepressant Drug
7.7 Others
Chapter 8. Global Bipolar Disorders and Treatment Market, by End User
8.1 Introduction
8.2 Hospitals and Clinics
8.3 Multispecialty Centers
8.4 Others
Chapter 9. Global Bipolar Disorders Treatment Market, by Region
9.1 Introduction
9.2 America
9.2.1 North America
9.2.1.1 US
9.2.1.2 Canada
9.2.2 Latin America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 UK
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia-Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia-Pacific
9.5 Middle East & Africa
9.5.1 Middle East
9.5.2 Africa
Chapter 10. Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments
Chapter 11 Company Profiles
11.1 Allergan
11.1.1 Company Overview
11.1.2 Drug Type Overview
11.1.3 Financials Overview
11.1.4 Key Developments
11.1.5 SWOT Analysis
11.2 Baxter International, Inc.
11.2.1 Company Overview
11.2.2 Drug Type Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 AstraZeneca
11.3.1 Company Overview
11.3.2 Drug Type Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 Eli Lilly and Company
11.4.1 Company Overview
11.4.2 Technologys/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 GlaxoSmithKline
11.5.1 Company Overview
11.5.2 Drug Type Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.5.5 SWOT Analysis
11.6 Abbott
11.6.1 Company Overview
11.6.2 Drug Type Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.6.5 SWOT Analysis
11.7 Bristol-Myers Squibb
11.7.1 Overview
11.7.2 Drug Type Overview
11.7.3 Financial Overview
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 Johnson & Johnson
11.8.1 Overview
11.8.2 Drug Type/ Technology Overview
11.8.3 Financials
11.8.4 Key Developments
11.8.5 SWOT Analysis
11.9 Pfizer Inc.
11.9.1 Overview
11.9.2 Drug Type Overview
11.9.3 Financials
11.9.4 Key Developments
11.9.5 SWOT Analysis
11.10 Cephalon Inc.
11.10.1 Overview
11.10.2 Drug Type Overview
11.10.3 Financials
11.10.4 Key Developments
11.10.5 SWOT Analysis
11.11 Otsuka America Pharmaceutical Inc.
11.11.1 Overview
11.11.2 Drug Type Overview
11.11.3 Financials
11.11.4 Key Developments
11.11.5 SWOT Analysis
11.12 Gedeon Richter plc
11.12.1 Overview
11.12.2 Drug Type Overview
11.12.3 Financials
11.12.4 Key Developments
11.12.5 SWOT Analysis
11.13 Others
Chapter 12. Appendix
LIST OF TABLES
Table 1 Global Bipolar Disorders Treatment Synopsis, 2020-2027
Table 2 Global Bipolar Disorders Treatment Market Estimates and Forecast, 2020-2027, (USD Million)
Table 3 Global Bipolar Disorders Treatment Market, by Region 2020-2027, (USD Million)
Table 4 Global Bipolar Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)
Table 5 Global Bipolar Disorders Treatment Market, by Mechanism of Action 2020-2027, (USD Million)
Table 6 Global Bipolar Disorders Treatment Market, by End User 2020-2027, (USD Million)
Table 7 North America: Bipolar Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)
Table 8 North America: Bipolar Disorders Treatment Market, by Mechanism of Action 2020-2027, (USD Million)
Table 9 North America: Bipolar Disorders Treatment Market, by End User 2020-2027, (USD Million)
Table 10 US: Bipolar Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)
Table 11 US: Bipolar Disorders Treatment Market, by Mechanism of Action 2020-2027, (USD Million)
Table 12 US: Bipolar Disorders Treatment Market, by End User 2020-2027, (USD Million)
Table 13 Canada: Bipolar Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)
Table 14 Canada: Bipolar Disorders Treatment Market, by Mechanism of Action 2020-2027, (USD Million)
Table 15 Canada: Bipolar Disorders Treatment Market, by End User 2020-2027, (USD Million)
Table 16 Latin America: Bipolar Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)
Table 17 Latin America: Bipolar Disorders Treatment Market, by Mechanism of Action 2020-2027, (USD Million)
Table 18 Latin America: Bipolar Disorders Treatment Market, by End User 2020-2027, (USD Million)
Table 19 Europe: Bipolar Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)
Table 20 Europe: Bipolar Disorders Treatment Market, by Mechanism of Action 2020-2027, (USD Million)
Table 21 Europe: Bipolar Disorders Treatment Market, by End User 2020-2027, (USD Million)
Table 22 Western Europe: Bipolar Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)
Table 23 Western Europe: Bipolar Disorders Treatment Market, by Mechanism of Action 2020-2027, (USD Million)
Table 24 Western Europe: Bipolar Disorders Treatment Market, by End User 2020-2027, (USD Million)
Table 25 Eastern Europe: Bipolar Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)
Table 26 Eastern Europe: Bipolar Disorders Treatment Market, by Mechanism of Action 2020-2027, (USD Million)
Table 27 Eastern Europe: Bipolar Disorders Treatment Market, by End User 2020-2027, (USD Million)
Table 28 Asia-Pacific: Bipolar Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)
Table 29 Asia-Pacific: Bipolar Disorders Treatment Market, by Mechanism of Action 2020-2027, (USD Million)
Table 30 Asia-Pacific: Bipolar Disorders Treatment Market, by End User 2020-2027, (USD Million)
Table 31 Middle East & Africa: Bipolar Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)
Table 32 Middle East & Africa: Bipolar Disorders Treatment Market, by Mechanism of Action 2020-2027, (USD Million)
Table 33 Middle East & Africa: Bipolar Disorders Treatment Market, by End User 2020-2027, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation of the Global Bipolar Disorders Treatment Market
Figure 3 Segmentation Market Dynamics for the Global Bipolar Disorders Treatment Market
Figure 4 Global Bipolar Disorders Treatment Market Share, by Drug Type, 2020
Figure 5 Global Bipolar Disorders Treatment Market Share, by Mechanism of Action, 2020
Figure 6 Global Bipolar Disorders Treatment Market Share, by End User, 2020
Figure 7 Global Bipolar Disorders Treatment Market Share, by Region, 2020
Figure 8 North America: Bipolar Disorders Treatment Market Share, by Country, 2020
Figure 9 Europe: Bipolar Disorders Treatment Market Share, by Country, 2020
Figure 10 Asia-Pacific: Bipolar Disorders Treatment Market Share, by Country, 2020
Figure 11 Middle East & Africa: Bipolar Disorders Treatment Market Share, by Country, 2020
Figure 12 Global Bipolar Disorders Treatment Market: Company Share Analysis, 2020 (%)
Figure 13 Allergan: Key Financials
Figure 14 Allergan: Segmental Revenue
Figure 15 Allergan: Geographical Revenue
Figure 16 Baxter International, Inc.: Key Financials
Figure 17 Baxter International, Inc.: Segmental Revenue
Figure 18 Baxter International, Inc.: Geographical Revenue
Figure 19 AstraZeneca: Key Financials
Figure 20 AstraZeneca.: Segmental Revenue
Figure 21 AstraZeneca: Geographical Revenue
Figure 22 Eli Lilly and Company.: Key Financials
Figure 23 Eli Lilly and Company: Segmental Revenue
Figure 24 Eli Lilly and Company: Geographical Revenue
Figure 25 GlaxoSmithKline: Key Financials
Figure 26 GlaxoSmithKline: Segmental Revenue
Figure 27 GlaxoSmithKline: Geographical Revenue
Figure 28 Abbott: Key Financials
Figure 29 Abbott: Segmental Revenue
Figure 30 Abbott: Geographical Revenue
Figure 31 Bristol-Myers Squibb: Key Financials
Figure 32 Bristol-Myers Squibb: Segmental Revenue
Figure 33 Bristol-Myers Squibb: Geographical Revenue
Figure 34 Johnson & Johnson: Key Financials
Figure 35 Johnson & Johnson: Segmental Revenue
Figure 36 Johnson & Johnson: Geographical Revenue
Figure 37 Pfizer Inc.: Key Financials
Figure 38 Pfizer Inc.: Segmental Revenue
Figure 39 Pfizer Inc.: Geographical Revenue
Figure 40 Cephalon Inc.: Key Financials
Figure 41 Cephalon Inc.: Segmental Revenue
Figure 42 Cephalon Inc.: Geographical Revenue
Figure 43 Otsuka America Pharmaceutical Inc.: Key Financials
Figure 44 Otsuka America Pharmaceutical Inc.: Segmental Revenue
Figure 45 Otsuka America Pharmaceutical Inc.: Geographical Revenue
Figure 46 Gedeon Richter plc: Key Financials
Figure 47 Gedeon Richter plc: Segmental Revenue
Figure 48 Gedeon Richter plc: Geographical Revenue
